## **Core Concept**
The question tests the understanding of managing infections caused by Extended-Spectrum Beta-Lactamase (ESBL) producing bacteria, specifically *Klebsiella*, and the appropriate antibiotic therapy. ESBL-producing bacteria are resistant to most beta-lactam antibiotics, including penicillins, cephalosporins, and aztreonam.

## **Why the Correct Answer is Right**
For ESBL-producing *Klebsiella* infections, the current antibiotic regimen of ceftriaxone (a cephalosporin) and amikacin (an aminoglycoside) may not be sufficient due to the resistance pattern of ESBL producers. Ceftriaxone is ineffective against ESBL-producing bacteria, while amikacin might still be effective but using it alone or without a proper synergistic or bactericidal agent could be problematic. The best approach would be to switch to antibiotics that are effective against ESBL-producing bacteria. Carbapenems (like meropenem, imipenem, or doripenem) are generally the drugs of choice for serious infections caused by ESBL-producing organisms.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and cannot be evaluated.
- **Option B:** This option is blank and cannot be evaluated.
- **Option C:** This option is blank and cannot be evaluated.
- **Option D:** This option is blank and cannot be evaluated.

## **Clinical Pearl / High-Yield Fact**
A crucial point to remember is that for ESBL-producing organisms, carbapenems are considered the drugs of choice. If a patient is already on broad-spectrum antibiotics like ceftriaxone and amikacin for a suspected or confirmed ESBL infection, confirming the ESBL production should prompt a review of the antibiotics to ensure they are effective, typically leading to the use of a carbapenem.

## **Correct Answer:** D. Change antibiotics to a carbapenem (e.g., meropenem).